Skip to main content
SpringerLink
Log in

Different Expression of S100A8 in Malignant and Benign Gallbladder Diseases

  • Original Article
  • Published:
Digestive Diseases and Sciences Aims and scope Submit manuscript

Abstract

Background

Proteomic analysis is a powerful tool for complete establishment of protein expression. Comparative proteomic analysis of human bile from malignant and benign gallbladder diseases may be helpful in research into gallbladder cancer.

Aims

Our objective was to establish biliary protein content for gallbladder cancer, gallbladder adenoma, and chronic calculous cholecystitis for comparative proteomic analysis.

Methods

Bile samples were collected from patients with gallbladder cancer, gallbladder adenoma, and chronic calculous cholecystitis. Peptides of biliary proteins were separated by two-dimensional liquid chromatography then identified by tandem mass spectrometry.

Results

Up to 544, 221, and 495 unique proteins were identified in bile samples from gallbladder cancer, gallbladder adenoma, and chronic calculous cholecystitis. Forty-three, 16, and 28 proteins with more than one unique peptide, respectively, were identified in the three groups. Among these, 30 proteins including S100A8 were overexpressed in gallbladder cancer, compared with benign gallbladder diseases. We also confirmed, by immunohistochemical analysis, that S100A8 is more abundant in tumor-infiltrating immune cells in cancerous tissue.

Conclusions

Compared with benign gallbladder diseases, consistently elevated S100A8 levels in malignant gallbladder bile and tissue indicate that gallbladder cancer is an inflammation-associated cancer. S100A8 may be a biomarker for gallbladder cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

Notes

  1. \( emPAI = 10\frac{{N_{\text{observed}} }}{{N_{\text{observable}} }} - 1 \) where N observed is the number of experimentally observed peptides and N observable is the calculated number of observable peptides for each protein.

References

  1. Pitt HA. Gallbladder cancer: what is an aggressive approach? Ann Surg. 2005;241:395–396.

    Article  PubMed  Google Scholar 

  2. Shukla HS. Gallbladder Cancer. J Surg Oncol. 2006;93:604–606.

    Article  PubMed  CAS  Google Scholar 

  3. Nedelkov D, Kiernan UA, Niederkofler EE, Tubbs KA, Nelson RW. Population proteomics: the concept, attributes, and potential for cancer biomarker research. Mol Cell Proteom. 2006;5:1811–1818.

    Article  CAS  Google Scholar 

  4. Simpson RJ, Dorow DS. Cancer proteomics: from signaling networks to tumor markers. Trends Biotechnol. 2001;19:40–48.

    Article  Google Scholar 

  5. Chen CY, Tsai WL, Wu HC, et al. Diagnostic role of biliary pancreatic elastase for cholangiocarcinoma in patients with cholestasis. Clin Chim Acta. 2008;390:82–89.

    Article  PubMed  CAS  Google Scholar 

  6. He QY, Cheung YH, Leung SY, Yuen ST, Chu KM, Chiu JF. Diverse proteomic alterations in gastric adenocarcinoma. Proteomics. 2004;4:3276–3287.

    Article  PubMed  CAS  Google Scholar 

  7. Petricoin EF, Liotta LA. SELDI-TOF-based serum proteomic pattern diagnostics for early detection of cancer. Curr Opin Biotechnol. 2004;15:24–30.

    Article  PubMed  CAS  Google Scholar 

  8. Farina A, Dumonceau JM, Frossard JL, Hadengue A, Hochstrasser DF, Lescuyer P. Proteomic analysis of human bile from malignant biliary stenosis induced by pancreatic cancer. J Proteome Res. 2009;8:159–169.

    Article  PubMed  CAS  Google Scholar 

  9. Niu D, Feng H, Chen WN. Proteomic analysis of HBV-associated HCC: insights on mechanisms of disease onset and biomarker discovery. J Proteomics. 2010;73:1283–1290.

    Article  PubMed  CAS  Google Scholar 

  10. Wang JW, Peng SY, Li JT, et al. Identification of metastasis-associated proteins involved in gallbladder carcinoma metastasis by proteomic analysis and functional exploration of chloride intracellular channel 1. Cancer Lett. 2009;281:71–81.

    Article  PubMed  CAS  Google Scholar 

  11. Bonney GK, Craven RA, Prased R, et al. Circulating markers of biliary malignancy: opportunities in proteomics? Lancet Oncol. 2008;9:149–158.

    Article  PubMed  CAS  Google Scholar 

  12. Guerrier L, Claverol S, Finzi L, et al. Contribution of solid-phase hexapeptide ligand libraries to the repertoire of human bile proteins. J Chromatogr A. 2007;1176:192–205.

    Article  PubMed  CAS  Google Scholar 

  13. Kristiansen TZ, Bunkenborg J, Gronborg M, et al. A proteomic analysis of human bile. Mol Cell Proteom. 2004;3:715–728.

    Article  CAS  Google Scholar 

  14. Liu Y, Wu J, Yan G, et al. Proteomic analysis of prolactinoma cells by immuno-laser capture microdissection combined with online two-dimensional nano-scale liquid chromatography/mass spectrometry. Proteome Sci. 2010;8:2.

    Article  PubMed  Google Scholar 

  15. Ishihama Y, Oda Y, Tabata T, et al. Exponentially modified protein abundance index (emPAI) for estimation of absolute protein amount in proteomics by the number of sequenced peptides per protein. Mol Cell Proteom. 2005;4:1265–1272.

    Article  CAS  Google Scholar 

  16. Zhou H, Chen B, Li RX, et al. Large-scale identification of human biliary proteins from a cholesterol stone patient using a proteomic approach. Rapid Commun Mass Spectrom. 2005;19:3569–3578.

    Article  PubMed  CAS  Google Scholar 

  17. Lankisch TO, Metzger J, Negm AA, et al. Bile proteomic profiles differentiate cholangiocarcinoma from primary sclerosing cholangitis and choledocholithiasis. Hepatology. 2011;53:875–884.

    Article  PubMed  CAS  Google Scholar 

  18. Sheikh AA, Vimalachandran D, Thompson CC, et al. The expression of S100A8 in pancreatic cancer-associated monocytes is associated with the Smad4 status of pancreatic cancer cells. Proteomics. 2007;7:1929–1940.

    Article  PubMed  CAS  Google Scholar 

  19. Washiro M, Ohtsuka M, Kimura F, et al. Upregulation of topoisomerase IIalpha expression in advanced gallbladder carcinoma: a potential chemotherapeutic target. J Cancer Res Clin Oncol. 2008;134:793–801.

    Article  PubMed  CAS  Google Scholar 

  20. Kellner U, Sehested M, Jensen PB, Gieseler F, Rudolph P. Culprit and victim—DNA topoisomerase II. Lancet Oncol. 2002;3:235–243.

    Article  PubMed  CAS  Google Scholar 

  21. Farina A, Dumonceau JM, Delhaye M, Frossard JL, Hadengue A, Hochstrasser DF, Lescuyer P. A step further in the analysis of human bile proteome. J Proteome Res. Epub. 02/11/2011.

  22. Farina A, Dumonceau JM, Lescuyer P. Proteomic analysis of human bile and potential applications for cancer diagnosis. Expert Rev Proteom. 2009;6:285–301.

    Article  CAS  Google Scholar 

  23. Lo WY, Lai CC, Hua CH, et al. S100A8 is identified as a biomarker of HPV18-infected oral squamous cell carcinomas by suppression subtraction hybridization, clinical proteomic analysis, and immunohistochemistry staining. J Proteome Res. 2007;6:2143–2151.

    Article  PubMed  CAS  Google Scholar 

  24. Gebhardt C, Nemeth J, Angel P, Hess J. S100A8 and S100A9 in inflammation and cancer. Biochem Pharmacol. 2006;72:1622–1631.

    Article  PubMed  CAS  Google Scholar 

  25. Nacken W, Roth J, Sorg C, Kerkhoff C. S100A9/S100A8: Myeloid representatives of the S100 protein family as prominent players in innate immunity. Microsc Res Tech. 2003;60:569–580.

    Article  PubMed  CAS  Google Scholar 

  26. Lundy FT, Chalk R, Lamey PJ, Shaw C, Linden GJ. Identification of MRP-8 (calgranulin A) as a major responsive protein in chronic periodontitis. J Pathol. 2000;192:540–544.

    Article  PubMed  CAS  Google Scholar 

  27. de Seny D, Fillet M, Ribbens C, et al. Monomeric calgranulins measured by SELDI-TOF mass spectrometry and calprotectin measured by ELISA as biomarkers in arthritis. Clin Chem. 2008;54:1066–1075.

    Article  PubMed  Google Scholar 

  28. Rafii S, Lyden D. S100 chemokines mediate bookmarking of premetastatic niches. Nat Cell Biol. 2006;8:1321–1323.

    Article  PubMed  CAS  Google Scholar 

  29. Hiratsuka S, Watanabe A, Aburatani H, Maru Y. Tumour-mediated upregulation of chemoattractants and recruitment of myeloid cells predetermines lungmetastasis. Nat Cell Biol. 2006;8:1369–1375.

    Article  PubMed  CAS  Google Scholar 

  30. El-Rifai W, Moskaluk CA, Abdrabbo MK, et al. Gastric cancers overexpress S100A calcium-binding proteins. Cancer Res. 2002;62:6823–6826.

    PubMed  CAS  Google Scholar 

  31. Kim HJ, Kang HJ, Lee H, et al. Identification of S100A8 and S100A9 as serological markers for colorectal cancer. J Proteome Res. 2009;8:1368–1379.

    Article  PubMed  CAS  Google Scholar 

  32. Hermani A, Hess J, De Servi B, et al. Calcium-binding proteins S100A8 and S100A9 as novel diagnostic markers in human prostate cancer. Clin Cancer Res. 2005;11:5146–5152.

    Article  PubMed  CAS  Google Scholar 

  33. Cross SS, Hamdy FC, Deloulme JC, Rehman I. Expression of S100 proteins in normal human tissues and common cancers using tissue microarrays: S100A6, S100A8, S100A9 and S100A11 are all overexpressed in common cancers. Histopathology. 2005;46:256–269.

    Article  PubMed  CAS  Google Scholar 

  34. de Visser KE, Eichten A, Coussens LM. Paradoxical roles of the immune system during cancer development. Nat Rev Cancer. 2006;6:24–37.

    Article  PubMed  Google Scholar 

  35. Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow? Lancet. 2001;357:539–545.

    Article  PubMed  CAS  Google Scholar 

  36. Goldin RD, Roa JC. Gallbladder cancer: a morphological and molecular update. Histopathology. 2009;55:218–229.

    Article  PubMed  Google Scholar 

Download references

Acknowledgments

The authors thank Guoquan Yan (Institutes of Biomedical Sciences, Fudan University, China) for proteomics support. This research was funded by grants from Science and Technology Commission of Shanghai (no. 09411964600) and the Education Commission of Shanghai (no. 09zz22).

Conflicts of interest

No conflict of interest exits in the submission of this manuscript.

Author information

Authors and Affiliations

  1. Department of General Surgery, The 6th Affiliated Hospital of Shanghai Jiaotong University, 600 Yishan Road, Shanghai, 200233, China

    Kai-Xing Ai, Zhou Yuan & Xin-Yu Huang

  2. Department of General Surgery, Shaoxing People’s Hospital, Shaoxing Hospital of Zhejiang University, Zhejiang, 312000, China

    Wei Wang

  3. Department of Pathology, The 6th Affiliated Hospital of Shanghai Jiaotong University, Shanghai, 200233, China

    Hui-Zhen Zhang

Authors
  1. Wei Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Kai-Xing Ai
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Zhou Yuan
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Xin-Yu Huang
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Hui-Zhen Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Kai-Xing Ai.

Additional information

Kai-Xing Ai and Wei Wang contributed equally to this work.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Wang, W., Ai, KX., Yuan, Z. et al. Different Expression of S100A8 in Malignant and Benign Gallbladder Diseases. Dig Dis Sci 58, 150–162 (2013). https://doi.org/10.1007/s10620-012-2307-0

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10620-012-2307-0

Keywords

Search

Navigation